Identification of Widely Applicable Tumor-Associated Antigens for Breast Cancer Immunotherapy
Abstract
This study is the initial phase (the 1st year) of a feasibility study of a novel immunotherapeutic strategy for the treatment of breast cancer. The rationale is based upon recent findings that genes belonging to the pp32 family are differentially and alternatively expressed in most human breast cancers. In general, benign breast tissues express pp32, a tumor suppressor, whereas breast cancers express tumorigenic family members, including pp32r1 and pp32r2. Since pp32r1 and pp32r2 are expressed in nearly all breast cancers, but not in normal adult tissues, they may reasonably serve as targets for antigen-specific immunotherapy. The purpose of the study is to identify tumor-associated antigens (TAA) in pp32r1 and pp32r2, then test their suitability in vitro as immunotherapeutic targets in breast cancer. Currently, the second phase of (in vivo) feasibility is underway. If successful, the results may translate into eventual clinical trials of peptide vaccines or adoptive T-cell therapy. (2 tables, 1 figure)
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2002
- Accession Number
- ADA411919
Entities
People
- Jining Bai
Organizations
- Johns Hopkins University